Author

J. Cheah

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Scientific Communication & Education· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Assay:clinical cohort / trial· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. Chaudhri· 1 shared A. Ismail· 1 shared A. Lazar· 1 shared A. M. Nur· 1 shared A. N. Yin· 1 shared A. Shi· 1 shared A. Singh· 1 shared C. Bernatchez· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Chaudhri

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy Resistance

M. Maitituoheti, A. Shi, M. Tang, L.-L. Ho, C. Terranova, K. Galani, E. Keung, C. Creasy, M. Wu, J. Chen, N. Chen, A. Singh, A. Chaudhri, N. Anvar, G. Tarantino, , K. Rai

The paper identifies enhancer-based biomarkers of resistance to anti-PD-1 therapy in melanoma and suggests enhancer blockade combined with ICB as a potential strategy to improve treatment responses.

bioRxiv · Aug 31, 2022 · PreprintCancer Biology

Generation of dual specific bivalent BiTEs (dbBIspecific T-cell Engaging antibodies) for cellular immunotherapy

M. Kujawski, L. Li, S. Bhatacharya, P. Wong, W.-H. Lee, L. (Obrien) Williams, H. Li, J. Cheah, K. Poku, N. Bowles, N. Vaidehi, P. Yazaki, J. E. Shively

This paper describes the generation of dual-specific bivalent BiTES for cancer immunotherapy, showing they maintain tumor targeting and kill CEA+ cells in vitro and in vivo.

BMC Cancer · Dec 1, 2019Peer-reviewedCancer Biology

Economic Burden of Hypoglycaemia among Type II Diabetes Mellitus Patients in Malaysia.

S. M. Aljunid, A. N. Yin, A. Ismail, S. A. Z. Abdul Rashid, A. M. Nur, J. Cheah, P. Matzen

This study estimates the economic burden of hypoglycaemia in Malaysian Type II diabetes patients, finding it costs RM 117.4 million annually, equivalent to 0.5% of the Ministry of Health budget.

bioRxiv · Jan 11, 2019Scientific Communication & Education